Clinical Read2026-09-15

Ebribafusp (AKB-097 (ADX-097))

Akebia Therapeutics Inc.AKBA
Indication
IgA nephropathy, lupus nephritis and C3 glomerulopathy
Stage
phase2
Event
Phase 2